Teladoc Health (NYSE:TDOC - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of -1.350--1.000 for the period, compared to the consensus earnings per share estimate of -1.050. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q3 2025 guidance to EPS.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the company. Zacks Research raised Teladoc Health from a "hold" rating to a "strong-buy" rating in a research report on Friday, October 10th. Mizuho assumed coverage on Teladoc Health in a research report on Friday, July 25th. They set a "neutral" rating and a $10.00 target price on the stock. Evercore ISI raised their target price on Teladoc Health from $8.00 to $9.00 and gave the company an "in-line" rating in a research report on Wednesday, October 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Teladoc Health in a research report on Wednesday, October 8th. Finally, Citigroup lifted their price target on shares of Teladoc Health from $9.50 to $10.50 and gave the company a "neutral" rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $9.97.
Check Out Our Latest Analysis on Teladoc Health
Teladoc Health Trading Up 3.1%
NYSE:TDOC traded up $0.26 during trading hours on Thursday, reaching $8.60. 7,334,354 shares of the company were exchanged, compared to its average volume of 6,958,508. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.67 and a quick ratio of 2.58. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -7.22 and a beta of 1.90. Teladoc Health has a 52-week low of $6.35 and a 52-week high of $15.21. The stock has a 50 day simple moving average of $8.04 and a 200 day simple moving average of $7.64.
Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The health services provider reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.08. The company had revenue of $631.90 million for the quarter, compared to the consensus estimate of $621.91 million. Teladoc Health had a negative net margin of 8.16% and a negative return on equity of 10.13%. Teladoc Health's revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.38) earnings per share. Teladoc Health has set its Q3 2025 guidance at -0.350--0.200 EPS. FY 2025 guidance at -1.350--1.000 EPS. As a group, analysts predict that Teladoc Health will post -1.16 EPS for the current year.
Hedge Funds Weigh In On Teladoc Health
A number of hedge funds have recently made changes to their positions in TDOC. Envestnet Asset Management Inc. purchased a new position in shares of Teladoc Health in the 2nd quarter valued at $89,000. NewEdge Advisors LLC raised its stake in shares of Teladoc Health by 1,278.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider's stock valued at $90,000 after acquiring an additional 10,485 shares during the period. Manhattan West Asset Management LLC purchased a new position in shares of Teladoc Health in the 2nd quarter valued at $100,000. Corient Private Wealth LLC raised its stake in shares of Teladoc Health by 30.4% in the 2nd quarter. Corient Private Wealth LLC now owns 17,180 shares of the health services provider's stock valued at $149,000 after acquiring an additional 4,004 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Teladoc Health by 58.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 22,481 shares of the health services provider's stock worth $196,000 after acquiring an additional 8,254 shares in the last quarter. Hedge funds and other institutional investors own 76.82% of the company's stock.
About Teladoc Health
(
Get Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
